iBio, Inc. (IBIO) stock
IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.73−0.03 (-4.00%)
Close on Nov 13, 2026Market cap $47.05MP/E –Yield –
iBio profit margin
Profit margin (net margin) is net income as a percentage of revenue.
iBio's profit margin for the twelve months ending Sep 30, 2026 was -3244.2%. For fiscal 2026 it was -33044.0%, against -4594.3% the year before. The highest annual figure on record is -357.9% in fiscal 2015.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -33044.0% | −28449.8 |
| FY2025 | Jun 30, 2025 | -4594.3% | +6475.5 |
| FY2024 | Jun 30, 2024 | -11069.8% | −8399.8 |
| FY2022 | Jun 30, 2022 | -2670.0% | −1691.2 |
| FY2021 | Jun 30, 2021 | -978.8% | +24.8 |
| FY2020 | Jun 30, 2020 | -1003.6% | −131.8 |
| FY2019 | Jun 30, 2019 | -871.8% | +2755.4 |
| FY2018 | Jun 30, 2018 | -3627.3% | +61.1 |
| FY2017 | Jun 30, 2017 | -3688.3% | −2658.4 |
| FY2016 | Jun 30, 2016 | -1030.0% | −672.0 |
| FY2015 | Jun 30, 2015 | -357.9% | +1430.4 |
| FY2014 | Jun 30, 2014 | -1788.3% | −1172.8 |
| FY2013 | Jun 30, 2013 | -615.5% | −171.0 |
| FY2012 | Jun 30, 2012 | -444.5% | +1890.2 |
| FY2011 | Jun 30, 2011 | -2334.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | -702.4% | +3742.2 |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -5720.0% | +5772.0 |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -2581.5% | −1893.2 |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -2182.0% | −2205.6 |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -4444.6% | −3443.1 |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -11492.0% | −10339.0 |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -688.3% | +1149.0 |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | 23.6% | +339.5 |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -1001.4% | +3869.4 |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -1153.0% | +45.0 |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -1837.3% | +2295.1 |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -315.9% | +250.5 |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -4870.8% | −4069.5 |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -1198.1% | −511.6 |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -4132.4% | +5640.9 |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -566.4% | +4288.5 |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -801.3% | +4278.2 |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -686.5% | +1861.9 |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -9773.3% | −6637.3 |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -4854.9% | −1910.0 |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -5079.5% | +5496.2 |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -2548.4% | +1757.0 |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -3136.1% | −868.7 |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -2944.9% | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -10575.7% | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -4305.3% | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -2267.4% | – |
See a number that looks wrong?